Meglitinide

WikiDoc Resources for Meglitinide
Articles
Most recent articles on Meglitinide Most cited articles on Meglitinide Review articles on Meglitinide Articles on Meglitinide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Meglitinide Images of Meglitinide Photos of Meglitinide Podcasts & MP3s on Meglitinide Videos on Meglitinide
Evidence Based Medicine
Cochrane Collaboration on Meglitinide Bandolier on Meglitinide TRIP on Meglitinide
Clinical Trials
Ongoing Trials on Meglitinide at Clinical Trials.gov Trial results on Meglitinide Clinical Trials on Meglitinide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Meglitinide NICE Guidance on Meglitinide NHS PRODIGY Guidance FDA on Meglitinide CDC on Meglitinide
Books
Books on Meglitinide
News
Meglitinide in the news Be alerted to news on Meglitinide News trends on Meglitinide
Commentary
Blogs on Meglitinide
Definitions
Definitions of Meglitinide
Patient Resources / Community
Patient resources on Meglitinide Discussion groups on Meglitinide Patient Handouts on Meglitinide Directions to Hospitals Treating Meglitinide Risk calculators and risk factors for Meglitinide
Healthcare Provider Resources
Symptoms of Meglitinide Causes & Risk Factors for Meglitinide Diagnostic studies for Meglitinide Treatment of Meglitinide
Continuing Medical Education (CME)
CME Programs on Meglitinide
International
Meglitinide en Espanol Meglitinide en Francais
Business
Meglitinide in the Marketplace Patents on Meglitinide
Experimental / Informatics
List of terms related to Meglitinide

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

The meglitinide class of drugs treat diabetes type 2 by blocking the potassium channels in beta cells, which closes the ATP-dependent potassium channels and opens the cells' calcium channels. The resulting calcium influx causes the cells to secrete insulin.

Drugs

The main branded drug in the meglitinide class is Novo Nordisk's repaglinide (Prandin), which gained FDA approval in 1997. Another type of drug in this class is nateglinide (Starlix).

These drugs should be taken 0-30 minutes prior to eating. Follow the instructions given to you by your physician/nurse.

Side-effects

Side effects include weight gain and hypoglycemia. While the potential for hypoglycemia is less than for those on sulfonylureas, it is still a serious potential side effect that can be life-threatening. Patients on this medication should know the signs and symptoms of hypoglycemia and appropriate action to take. Template:SIB Template:Oral hypoglycemics Template:WH Template:WikiDoc Sources